Today: 3 March 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

CVU Stock Skyrockets 70% on Missile Contract Win – CPI Aerostructures Surges as Analysts Weigh In

CVU Stock Skyrockets 70% on Missile Contract Win – CPI Aerostructures Surges as Analysts Weigh In

CPI Aerostructures shares surged up to 75% intraday on Oct. 30 after announcing a major missile wing contract with Raytheon. The stock traded around $3.50–$3.70 by late morning, reversing from 52-week lows earlier in the week. The new order expands CPI’s presence in missile systems, with deliveries starting in 2026. Financial terms were not disclosed.
30 October 2025
···
Medical Properties Trust Defies Skeptics: Q3 Beat and Buyback Ignite 6%‑Yield REIT Rally

Medical Properties Trust Defies Skeptics: Q3 Beat and Buyback Ignite 6%‑Yield REIT Rally

Shares of Medical Properties Trust closed near $5.00 on Oct. 30, 2025, up 3–4% after Q3 earnings beat expectations, valuing the company at $3 billion. Management authorized a $150 million share buyback and reported improved rent collections. The REIT pays a quarterly dividend of $0.08 per share after recent cuts. Short interest remains high at 37% of float, while institutional ownership stands at 58%.
30 October 2025
··
Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience shares fell to $0.40 in October 2025, down 84% year-over-year, after hitting a 52-week low of $0.28. Nasdaq granted a 180-day extension to regain $1 compliance, and the company is considering a reverse split. Q2 revenue dropped 12% to $20.5 million, but cash flow improved. Debt refinancing is required by December 2025, and John Duke became CEO in July after Jim Green’s retirement.
30 October 2025
··
Plug Power’s 170% Hydrogen Rally Cools – Can PLUG Stock Reignite?

Plug Power’s 170% Hydrogen Rally Cools – Can PLUG Stock Reignite?

Plug Power shares soared about 170% from late summer lows to a $4.58 peak in early October, then dropped to around $2.8–$2.9 by Oct. 30. The company signed a 2 GW electrolyzer deal in Uzbekistan, raised $370 million, and secured major credit lines. Founder CEO Andy Marsh will step down in 2026. Analysts remain split, with targets ranging from $1 to $4.50.
30 October 2025
······
Intel (INTC) Stock Soars 90% to 18-Month High on AI Boom, $15B Lifeline – Will the Rally Last?

Intel (INTC) Stock Soars 90% to 18-Month High on AI Boom, $15B Lifeline – Will the Rally Last?

Intel stock has surged 85–90% year-to-date, hitting an 18-month high near $42 after a surprise Q3 return to profit and $13.7 billion in revenue. The U.S. government, Nvidia, and SoftBank invested $15 billion in 2025, with Washington taking a 10% stake. New CEO Lip-Bu Tan is steering Intel toward AI and advanced manufacturing. Analysts warn the stock’s valuation, now ~70× forward earnings, far exceeds peers.
30 October 2025
···
Ambev’s Profit Soars 36% in Q3 – Buyback Announced as ABEV Stock Eyes Rally

Ambev’s Profit Soars 36% in Q3 – Buyback Announced as ABEV Stock Eyes Rally

Ambev S.A. reported Q3 net income of 4.86 billion reais, up 36% year-on-year and well above analyst forecasts. Beer volumes fell 5.9%, but higher prices kept revenue flat; EBITDA was R$7.06 billion, beating estimates. The board approved a buyback of up to 208 million shares. Shares traded around $2.25 after results, with analysts split on outlook amid sector headwinds.
30 October 2025
··
FMC Stock Plunges Over 40% to Multi-Year Low After Shock Loss and Dividend Cut – Is a Turnaround Possible?

FMC Stock Plunges Over 40% to Multi-Year Low After Shock Loss and Dividend Cut – Is a Turnaround Possible?

FMC Corp shares plunged 42% to $16, their lowest since 2016, after the company posted a $569 million quarterly loss and slashed its dividend by 80%. Revenue fell 49% year-over-year, hit by a $510 million write-down tied to its India business. The company cut its 2024 outlook and announced President Ronaldo Pereira will step down December 15. Analysts downgraded the stock and trimmed price targets.
30 October 2025
·
Conduent’s Ticket Machine Revolution Debuts in Italy Amid Data Breach Fallout and Market Buzz

Conduent’s Ticket Machine Revolution Debuts in Italy Amid Data Breach Fallout and Market Buzz

Conduent launched its DOT1 ticket vending machine with SETA S.p.A. in Italy, offering contactless payments and real-time transit updates. The rollout comes as Conduent faces fallout from a data breach that exposed personal data of at least 4.5 million people in the U.S. The company spent $25 million on breach response and is under investigation. Conduent shares trade near $2.50, down 30% over the past year.
30 October 2025
···
Nvidia’s Record $5 Trillion Surge: AI Mega-Deals Propel NVDA Stock – Is $300 Next?

Nvidia’s Record $5 Trillion Surge: AI Mega-Deals Propel NVDA Stock – Is $300 Next?

Nvidia’s market value topped $5 trillion this week as shares hit $207, following major AI chip deals and new supercomputer plans. Revenue jumped 56% last quarter to $46.7 billion, with the company forecasting 54% growth next quarter. Rival chipmakers AMD and Qualcomm also surged on new AI partnerships, but analysts say Nvidia still dominates supply. Wall Street remains bullish, though some warn the stock is “priced for perfection.”
30 October 2025
··
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb reported Q3 adjusted EPS of $1.63 on $12.2 billion revenue, beating estimates, and raised its 2025 outlook. Shares rebounded 3–4% after hitting a 52-week low, with dividend yield now near 5.5%. New drugs like Opdivo and Eliquis outperformed, offsetting a sharp Revlimid decline. The company acquired Orbital Therapeutics and launched schizophrenia drug Cobenfy, posting $62 million in early sales.
30 October 2025
··
Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

Altria reported Q3 net revenue down 3% to $6.07 billion and adjusted EPS of $1.45, matching estimates. Shares fell nearly 4% pre-market, trading about 10% below recent highs. The company doubled its buyback program to $2 billion and raised its 2025 earnings outlook floor. Cigarette and oral tobacco sales declined, while NJOY e-cigarette sales remain halted due to a patent dispute.
30 October 2025
···
Cava Stock Plunges to 52-Week Low – Bargain Buy or More Pain Ahead?

Cava Stock Plunges to 52-Week Low – Bargain Buy or More Pain Ahead?

Cava Group shares fell to a 52-week low of $54.93 on Oct. 30, down nearly 55% in a year and 62% below post-IPO highs. Revenue rose 24% in the first half of 2025, but same-store sales growth slowed to 2.1% last quarter. Analysts remain split, with price targets ranging from $37.50 to $100. The company continues to expand, recently opening locations in Miami and Detroit.
30 October 2025
·
Mario, Donkey Kong, Metroid – Is Nintendo Assembling Its Own “Avengers” Cinematic Universe?

Mario, Donkey Kong, Metroid – Is Nintendo Assembling Its Own “Avengers” Cinematic Universe?

Nintendo announced The Super Mario Galaxy Movie for April 2026, with the original cast returning, after The Super Mario Bros. Movie grossed over $1 billion worldwide. A live-action Zelda film is in development for 2027, and a Donkey Kong animated spin-off is underway. Rumors point to a Metroid movie, with Brie Larson lobbying for the lead. Nintendo stock hit record highs in 2025, boosted by Switch 2 and film prospects.
30 October 2025
·
Trump-Xi Trade Truce Sends Stocks Tumbling – Markets Brace for Tech Earnings and Fed Moves

Trump-Xi Trade Truce Sends Stocks Tumbling – Markets Brace for Tech Earnings and Fed Moves

Trump and Xi agreed to a one-year pause on new tariffs and rare-earth export curbs at the Busan summit. U.S. tariffs on China will drop to 47%, and China will resume buying U.S. soybeans. U.S. stock futures slipped Thursday after record highs, as Fed Chair Powell signaled caution on further rate cuts. Alphabet shares jumped on strong earnings, while Microsoft and Meta fell premarket.
30 October 2025
········
Comcast Shocker: Cord-Cutting Slows, Wireless Soars in Q3 Earnings

Comcast Shocker: Cord-Cutting Slows, Wireless Soars in Q3 Earnings

Comcast Q3 net income fell 8.2% to $3.33 billion, but adjusted EPS of $1.12 and revenue of $31.2 billion beat forecasts. Broadband and pay-TV subscriber losses slowed, while Xfinity Mobile added a record 414,000 lines. Peacock’s EBITDA loss narrowed to $217 million, and theme park revenue rose nearly 19%. Free cash flow jumped 45% to $4.9 billion; shares rose about 2% pre-market.
30 October 2025
··
Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Mastercard reported Q3 2025 revenue of $8.60 billion, up 17% year-over-year, with net profit rising 20% to $3.96 billion. Shares traded near $570 in October, up about 8% year-to-date and close to their 52-week high. The company announced support for major US dollar stablecoins and is in late-stage talks to acquire crypto firm ZeroHash for up to $2 billion. About 80% of analysts rate the stock a buy.
30 October 2025
···
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Intensity Therapeutics shares surged nearly 200% on Oct. 30, 2025, after Phase 1/2 trial results for INT230-6 showed a 75% disease control rate and median survival of 11.9 months in advanced cancer patients. The stock traded around $0.27 with a market cap near $13.1 million and daily volume spiking to 279 million shares. INT230-6 is in late-stage trials for sarcoma and breast cancer.
30 October 2025
·
1 … 54 55 56 57 58 … 140
Go toTop